Indeed, for NSCLC patients with the EGFR mutation, not only did high PD-L1 expression negatively impact the efficacy of EGFR-TKIs, but PD-1 inhibitor therapy was also reported to be less effective in this subgroup of patients compared to those with wild-type EGFR as first-line therapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.